Biogen shares plunge nearly 30% after ending trial for potential blockbuster Alzheimer's drug - CNBC

[news]

Biogen shares plunge nearly 30% after ending trial for potential blockbuster Alzheimer's drug (https://www.cnbc.com/2019/03/21/biogen-shares-plunge-more-than-25percent-after-ending-trial-for-alzheimers-drug-aducanumab.html) CNBC
Biogen halts study of Alzheimer's drug, a blow to hopes for new treatment (https://www.statnews.com/2019/03/21/biogen-eisai-alzheimer-trial-stopped/) STAT
Biogen's Alzheimer's drug aducanumab implodes in a PhIII disaster -- wiping out $15B-plus in market cap (https://endpts.com/biogens-alzheimers-drug-aducanumab-implodes-in-a-phiii-disaster/) Endpoints News
Biogen Shares Plunge After Alzheimer’s Drug Setback (https://www.bloomberg.com/news/articles/2019-03-21/biogen-halts-study-of-alzheimer-s-treatment-as-study-falls-short) Bloomberg
Biogen hit by 'transformative failure' as it cans adacanumab tests (https://www.fiercebiotech.com/biotech/biogen-and-eisai-rocked-as-aducanumab-turns-out-to-be-a-dud) FierceBiotech
View full coverage on Google News (https://news.google.com/stories/CAAqOQgKIjNDQklTSURvSmMzUnZjbmt0TXpZd1NoTUtFUWlCbT duZWpZQU1FYkJPS0RkT2s1ajlLQUFQAQ?oc=5)

More... (https://www.cnbc.com/2019/03/21/biogen-shares-plunge-more-than-25percent-after-ending-trial-for-alzheimers-drug-aducanumab.html)